RxDoctor Payments Data

Peter Dicpinigaitis, MD

Critical Care Medicine · Bronx, NYNPI 1194815993

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $207,686 of the $241,286 with a category attached, or 86.1%. Merck accounts for 62.3% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2021 at $54,547 and has fallen 69.3% since, to $16,742 in 2025. Among critical care medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$241,286in general payments, 2019–2025

Across 161 payments — averaging $1498.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$150K
  • GSK$41K
  • Bayer$21K
  • Shionogi Inc$15K
  • Chiesi USA, Inc.$12K
  • Regeneron$650
  • plus $1K from 4 others
$20,957in research payments, 2019–2025

Across 6 payments — averaging $3492.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$19K
  • Chiesi USA, Inc.$2K

What the payments were for

  • Consulting fees$207,68686%
  • Speaking & faculty fees$10,3804%
  • Travel & lodging$20,8249%
  • Food & beverage$2,3961%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck81$150,298
GSK33$40,942
Bayer21$20,844
Shionogi Inc16$15,054
Chiesi USA, Inc.5$12,231
Regeneron1$650
E.r. Squibb & Sons, L.L.C.1$525
BD1$362
Cepheid1$256
Sanofi1$125

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$241,286 in reported general payments places this provider in the 95th percentile of 442 critical care medicine providers in New York.

See all critical care medicine providers in New York

Medicare billing

Part B allowed, 2024
$89,233
Medicare patients
164
Services billed
520

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Arnuity ElliptaFluticasone Furoate14$2,668
Amitriptyline Hcl48$526
Omeprazole37$257
Montelukast Sodium31$215
Prednisone24$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArnuity Ellipta$40,942$2,66814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 442 critical care medicine providers in New York.

Other critical care medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →